Sickle Cell Anemia in Children Clinical Trial
Official title:
Stroke Prevention With Hydroxyurea Enabled Through Research and Education (SPHERE): A Prospective Trial to Reduce Primary Stroke in Children With Sickle Cell Anaemia
This study will 1) Evaluate the prevalence of elevated (conditional or abnormal) transcranial Doppler (TCD) velocities in a cross-sectional analysis of children with Sickle Cell Anemia (SCA) living in Tanzania; 2) Obtain longitudinal data on TCD velocities in this population; and 3) Measure the effects of hydroxyurea therapy on TCD velocities and associated primary stroke risk.
Stroke Prevention with Hydroxyurea Enabled through Research and Education (SPHERE) is a single-center prospective phase 2 pilot study. It will enroll a convenience sample of children with SCA, obtain cross-sectional baseline data at enrolment, and follow them as a prospective cohort for a period of 24 months. The cohort will be divided into two arms based on the initial screening TCD result: 1) those who have a normal (less than 170 cm/sec time averaged mean velocity (TAMV)) initial screening TCD and will be an observation/control cohort; and 2) those who have an elevated initial screening TCD (either conditional (170-199 cm/sec) or abnormal (greater than or equal to 200 cm/sec) TAMV) and will be a treatment cohort that receives open-label hydroxyurea therapy as per the dosing and administration schedule. Those who are found to have a normal TCD at enrolment and are part of the observation/control cohort will undergo repeat TCD 12 months after enrolment. If the TCD at 12 months has changed to an elevated velocity (conditional or abnormal), the study participant can begin study treatment, but will not be included in the primary endpoint analysis. The primary hypothesis is after 12 months of hydroxyurea therapy, children with conditional TCD velocities will achieve a mean decrease of >15cm/sec from their baseline TCD TAMV. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06387758 -
Low Systemic/High Local Exercise Load in Peds SCD
|
N/A | |
| Completed |
NCT04579926 -
PINPOINT: Gaming Technology for SCD Pain
|
N/A | |
| Completed |
NCT03632876 -
Nutritional Outcomes After Vitamin A Supplementation in Subjects With SCD
|
N/A | |
| Recruiting |
NCT05285917 -
Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa
|
Phase 3 | |
| Completed |
NCT04301336 -
Different Treatment Modalities in the Management of the Painful Crisis in Pediatric Sickle- Cell Anemia
|
Phase 2/Phase 3 | |
| Completed |
NCT03176849 -
A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT
|
Phase 4 | |
| Active, not recruiting |
NCT04750707 -
Hydroxyurea Therapy for Neurological and Cognitive Protection in Pediatric Sickle Cell Anemia in Uganda ( BRAINSAFE-II )
|
Phase 3 | |
| Recruiting |
NCT05018728 -
The Effect of Voxelotor on Cerebral Hemodynamic Response in Children With Sickle Cell Anemia
|
Phase 2 | |
| Recruiting |
NCT04191213 -
Gum Arabic as Anti-oxidant, Anti-inflammatory and Fetal Hemoglobin Inducing Agent in Sickle Cell Anemia Patients
|
Phase 2/Phase 3 | |
| Completed |
NCT04844099 -
Dihydroartemisinin-Piperaquine or Sulphadoxine-Pyrimethamine for the Chemoprevention of Malaria in Sickle Cell Anaemia
|
Phase 3 | |
| Completed |
NCT04800809 -
The Afolabi Stroke Registry for Children and Young Adults With SCD in Northern Nigeria
|